GlobeNewsWire
17 Nov 2026, 02:43 UTC · 1h ago
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Impact · against what's priced in
The FDA approval of Cosentyx for polymyalgia rheumatica provides Novartis with a first-mover advantage in a new patient demographic (adults over 50). This expands the drug's indicated use and creates a new revenue stream beyond existing indications.
- NVS+0.60
No priced-in read yet





